FDA ap­proves J&J and Leg­end’s Carvyk­ti for sec­ond-line mul­ti­ple myelo­ma

The FDA has ex­pand­ed the la­bel for John­son & John­son and Leg­end Biotech’s mul­ti­ple myelo­ma CAR-T ther­a­py to make it a much ear­li­er treat­ment op­tion for pa­tients, J&J an­nounced late Fri­day night.

The reg­u­la­tor ap­proved Carvyk­ti for mul­ti­ple myelo­ma pa­tients who have re­ceived at least one pri­or line of ther­a­py. The cell ther­a­py was first ap­proved in 2022 as a fifth-line op­tion, mak­ing it avail­able on­ly to pa­tients who’d al­ready ex­haust­ed many of their treat­ment choic­es. It gen­er­at­ed $500 mil­lion in glob­al sales last year, and TD Cowen an­a­lysts ex­pect the ther­a­py to bring in $950 mil­lion in sales this year fol­low­ing the la­bel ex­pan­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER